Placebo News and Research

RSS

Scientists zero in on dose levels of "sacred mushroom"

Scientists at the Johns Hopkins University School of Medicine have zeroed in on the dose levels of the "sacred mushroom" chemical capable of yielding positive, life-changing experiences, while minimizing the chance of transient negative reactions in screened volunteers under supportive, carefully monitored conditions.

15 Jun 2011

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

New data from a pivotal study in more than 1,800 infants show that Novartis candidate vaccine Bexsero induces a robust immune response to meningococcal serogroup B when given alone or when co-administered with other routine vaccines.

15 Jun 2011

Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011

Meda presents new positive results from a Phase-III clinical trial of Dymista at the annual meeting of the European Academy of Allergy and Clinical Immunology (EAACI) in Istanbul, Turkey.

15 Jun 2011

TIA, CONRAD enter license agreement to manufacture and distribute Tenofovir1% gel in Africa

CONRAD and the South African Government's Technology Innovation Agency (TIA) today announced a license agreement that grants TIA the rights to manufacture and distribute Tenofovir1% gel in Africa.

15 Jun 2011

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it successfully completed patient enrollment in its phase II Contrast-Induced Acute Kidney Injury study with its oral drug candidate CRMD001.

14 Jun 2011

TWi Biotech enrolls over 50% of patients for AC-201 Phase IIb trial against Type II Diabetes

TWi Biotechnology Inc. announced today that the company has enrolled over 50% of the total 240 patients for the Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes.

14 Jun 2011

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

New findings from a multi-center, randomized, placebo-controlled clinical study of Deplin 15mg added to commonly prescribed antidepressants known as selective serotonin reuptake inhibitors showed that all patients who achieved remission at 30 days using Deplin 15mg adjuvant therapy, and who chose to enter a 12 month maintenance phase, maintained their remission after a year of treatment.

14 Jun 2011

GE Healthcare announces results of Optison heart ultrasound contrast agent presented at ASE

Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison- (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in improving suboptimal echocardiograms.

14 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical trial showing that patients who received four doses of its ToleroMune cat allergy vaccine over a 12-week period maintained a statistically significant reduction in symptoms one year later.

13 Jun 2011

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.

13 Jun 2011

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Incyte Corporation announced today additional symptom improvement and quality of life (QoL) results from COMFORT-I, a randomized, double-blinded, placebo-controlled Phase III trial of Incyte's JAK1 and JAK2 inhibitor, ruxolitinib, in patients with myelofibrosis (MF).

13 Jun 2011

Preliminary results from Edison's EPI-A0001 28-day phase 2A trial against Friedreich's ataxia

Edison Pharmaceuticals, Inc. announced today preliminary results obtained on a 28-day phase 2A clinical trial in Friedreich's ataxia. While the primary endpoint of glucose disposition index did not show statistically significant improvement, EPI-A0001 did significantly improve neurological function as assessed by the Friedreich's Ataxia Rating Scale.

10 Jun 2011

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex Pharmaceuticals Incorporated today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF).

10 Jun 2011

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.

10 Jun 2011

Non-alcoholic wheat beer has positive effect on athletes' health

Many amateur athletes have long suspected what research scientists for the Department of Preventative and Rehabilitative Sports Medicine of the Technische Universitaet Muenchen at Klinikum rechts der Isar have now made official: Documented proof, gathered during the world's largest study of marathons, "Be-MaGIC", that the consumption of non-alcoholic weissbier, or wheat beer, has a positive effect on athletes' health.

10 Jun 2011

Drugs for enlarged prostate raise cancer risk

According to health officials, this Thursday, a class of drugs meant to improve symptoms of an enlarged prostate gland may actually increase the chance of getting a more serious form of prostate cancer. However they also said the drugs' benefits outweigh the risks.

9 Jun 2011

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

9 Jun 2011

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck, known as MSD outside the United States and Canada, today announced changes to the prescribing information in the United States for the highest dose of simvastatin, 80 mg, and the use of simvastatin with certain other medicines.

9 Jun 2011

Placebo News and Research

Scientists zero in on dose levels of "sacred mushroom"

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011

TIA, CONRAD enter license agreement to manufacture and distribute Tenofovir1% gel in Africa

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

TWi Biotech enrolls over 50% of patients for AC-201 Phase IIb trial against Type II Diabetes

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

GE Healthcare announces results of Optison heart ultrasound contrast agent presented at ASE

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Preliminary results from Edison's EPI-A0001 28-day phase 2A trial against Friedreich's ataxia

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

Non-alcoholic wheat beer has positive effect on athletes' health

Drugs for enlarged prostate raise cancer risk

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News